Mostafa Abdelhakiem

Dr. Mostafa Abdelhakiem

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2024 in Xenobiotica
Verified
Journal Article
Closed access
KSKhloud Shendy
Khloud Shendy
KAKhaled Abdelkawy
Khaled Abdelkawy
AAAhmed Amin Ali
Ahmed Amin Ali
FBFathalla Belal
Fathalla Belal
MAMostafa Abdelhakiem
Mostafa Abdelhakiem
Fawzy ElbarbryFawzy Elbarbry
Fawzy Elbarbry
1. Polymorphisms in genes coding folate-metabolizing enzymes might alter the pharmacokinetics and sensitivity for methotrexate "MTX".2. The aim of the study aimed to investigate the influence of MTHFR C677T, DHFR19 Ins/del, GGH -401 C > T, and MTR A2756G polymorphisms on MTX toxicity and pharmacokinetics in Egyptian patients with Acute lymphoblastic leukaemia (ALL) or Non-Hodgkin lymphoma (NHL).3. Fifty adult Egyptian patients with ALL and NHL, treated with high dose MTX, were prospectively enrolled in the study. Clinical and biochemical data was collected objectively from medical records after each cycle of MTX. Plasma concentrations of MTX were measured after 72 h of initiation of infusion. Genotyping was done with a PCR-ARMS and PCR-RFLP assays.4. The MTHFR C677T T variants significantly increased the risk of leukopenia, whereas the genotype MTHFR 677C > T TT significantly associated with lymphocytopenia, thrombocytopenia, and anemia. The genotype GGH-401 TT was significantly correlated with anemia. Plasma MTX level was significantly higher in patients with MTR A2756G G variants.5. MTHFR polymorphism played the main role in MTX toxicities. The pharmacokinetics of MTX was affected by MTR polymorphism. GGH mutation was mainly concerned with anemia. Pharmacogenetic testing are recommended to optimize MTX therapy.

7 February 2025 in Cancers
Verified
Journal Article
Open access
PDF file
OHOmar Hamdy
Omar Hamdy
KAKhalid Atallah
Khalid Atallah
AEAlyaa R. Elsergany
Alyaa R. Elsergany
SASara Atwa
Sara Atwa
RARana Abdo
Rana Abdo
MAMostafa Abdelhakiem
Mostafa Abdelhakiem
Background: This study aimed to evaluate the lymph node (LN) response in Her2-positive breast cancer patients who received neoadjuvant therapy (NAT) and to discuss if axillary staging can be omitted in these patients. Methods: This is a retrospective cohort study including patients with Her2+ breast cancer at our center from March 2022 to September 2023. Results: The study included 139 patients in the final analysis; 69.1% of the patients had HR+/Her2+ disease while 30.9% had HR−/Her2+ disease. Most of the included patients (129 patients = 92.8%) had initially node-positive or suspicious disease. A total of 112 patients (80.6%) showed clinically negative axillary LNs (cN0) after NAT. All of them showed pathologically node-negative disease. When comparing the pathological node-positive vs. -negative groups, the following was found to be statistically significant: degree of Her2 positivity, number of anti-Her2 cycles, pre- and post-neoadjuvant LN status, and primary tumor radiological and pathological response. Also, all T1 tumors before NAT showed negative LNs after NAT, but it was statistically non-significant. Conclusions: Axillary staging may be omitted in Her2+ patients with cN0 after NAT, especially those with early tumors, strong Her2+ disease, cN0 before NAT, and those in whom the primary tumor achieved a complete clinical response.

9 July 2026 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
ASAbdullah Saad
Abdullah Saad
BKBarina Khan
Barina Khan
ABAhmed Reda Bahr
Ahmed Reda Bahr
MAMostafa Abdelhakiem
Mostafa Abdelhakiem